FI954965A0 - AMPA-antagonister och behandlingsmetod där dessa används - Google Patents

AMPA-antagonister och behandlingsmetod där dessa används

Info

Publication number
FI954965A0
FI954965A0 FI954965A FI954965A FI954965A0 FI 954965 A0 FI954965 A0 FI 954965A0 FI 954965 A FI954965 A FI 954965A FI 954965 A FI954965 A FI 954965A FI 954965 A0 FI954965 A0 FI 954965A0
Authority
FI
Finland
Prior art keywords
alkyl
hydrogen
treatment method
benzyl
phenyl
Prior art date
Application number
FI954965A
Other languages
English (en)
Finnish (fi)
Other versions
FI954965A (sv
Inventor
Frank Waetjen
Joergen Drejer
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK55893A external-priority patent/DK55893D0/da
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of FI954965A0 publication Critical patent/FI954965A0/sv
Publication of FI954965A publication Critical patent/FI954965A/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
FI954965A 1993-05-13 1995-10-18 AMPA-antagonister och behandlingsmetod där dessa används FI954965A (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK55893A DK55893D0 (da) 1993-05-13 1993-05-13 Nye receptoraktive forbindelser, deres fremstilling og anvendelse
DK13894 1994-02-02
PCT/EP1994/001492 WO1994026747A1 (en) 1993-05-13 1994-05-09 Ampa antagonists and a method of treatment therewith

Publications (2)

Publication Number Publication Date
FI954965A0 true FI954965A0 (sv) 1995-10-18
FI954965A FI954965A (sv) 1995-11-10

Family

ID=26063386

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954965A FI954965A (sv) 1993-05-13 1995-10-18 AMPA-antagonister och behandlingsmetod där dessa används

Country Status (13)

Country Link
EP (1) EP0698025B1 (sv)
JP (1) JP3439215B2 (sv)
AT (1) ATE161259T1 (sv)
AU (1) AU679075B2 (sv)
CA (1) CA2161783C (sv)
DE (1) DE69407407T2 (sv)
DK (1) DK0698025T3 (sv)
ES (1) ES2111930T3 (sv)
FI (1) FI954965A (sv)
GR (1) GR3026008T3 (sv)
NO (1) NO305287B1 (sv)
NZ (1) NZ267081A (sv)
WO (1) WO1994026747A1 (sv)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
AU4423496A (en) * 1995-03-14 1996-10-02 Warner-Lambert Company Novel glutamate (ampa/kainate) receptor antagonists: n-substituted fused azacycloalkylquinoxalinediones
US5614508A (en) * 1995-06-07 1997-03-25 Warner-Lambert Company Amino acid derivatives of substituted quinoxaline 2,3-dione derivatives as glutamate receptor antagonists
US5874426A (en) * 1995-06-07 1999-02-23 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US6110911A (en) * 1995-06-07 2000-08-29 Warner-Lambert Company Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US5654303A (en) * 1995-06-07 1997-08-05 Warner-Lambert Company Alkyl amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
US5566694A (en) * 1995-06-07 1996-10-22 Allegheny Plastics, Inc. Continuous pickling tank with expandable seals
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
WO1998027097A1 (en) * 1996-12-16 1998-06-25 Warner-Lambert Company Tricyclic quinoxaline derivatives as neuroprotective agents
US6172065B1 (en) 1997-03-04 2001-01-09 Warner-Lambert Company Urea and thiourea derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
ATE285772T1 (de) * 1998-03-31 2005-01-15 Neurosearch As Verwendung von indol-2,3-dione-3-oximderivate als ampa-antagonisten
US6096744A (en) * 1998-05-04 2000-08-01 Warner-Lambert Company Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
AU4910500A (en) 1999-05-19 2000-12-12 Neurosearch A/S Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
CN1298704C (zh) 2000-01-24 2007-02-07 神经研究公司 具有神经营养活性的靛红衍生物
DE10121215A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh Dihydro-imidazo[4,5-e]indol- und 7H-Pyrrolo[3,2-f]chinoxalin Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
CA2630617C (en) 2005-11-23 2014-03-25 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
CA2652307A1 (en) * 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK146787A (da) * 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
CA2076948C (en) * 1991-08-28 2002-04-16 Frank Watjen Isatineoxime derivatives, their preparation and use
ES2109516T3 (es) * 1992-10-13 1998-01-16 Warner Lambert Co Derivados de quinoxalinodiona como antagonistas de aminoacidos excitadores.

Also Published As

Publication number Publication date
EP0698025A1 (en) 1996-02-28
WO1994026747A1 (en) 1994-11-24
JPH08510221A (ja) 1996-10-29
NO954576L (no) 1996-01-15
DE69407407D1 (de) 1998-01-29
AU679075B2 (en) 1997-06-19
DK0698025T3 (da) 1998-08-24
CA2161783A1 (en) 1994-11-24
FI954965A (sv) 1995-11-10
ATE161259T1 (de) 1998-01-15
DE69407407T2 (de) 1998-04-09
NZ267081A (en) 1997-11-24
AU6926494A (en) 1994-12-12
NO954576D0 (no) 1995-11-13
ES2111930T3 (es) 1998-03-16
GR3026008T3 (en) 1998-04-30
EP0698025B1 (en) 1997-12-17
JP3439215B2 (ja) 2003-08-25
NO305287B1 (no) 1999-05-03
CA2161783C (en) 2006-08-15

Similar Documents

Publication Publication Date Title
FI954965A0 (sv) AMPA-antagonister och behandlingsmetod där dessa används
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
ES8704925A1 (es) Un procedimiento para la preparacion de derivados de benzotiazol y benzotiofeno
ATE88714T1 (de) 2'-desoxy-5-fluoruridinderivate.
DK534381A (da) Fremgangsmaade til fremstilling af 2-oxoazetidinderivater
ATE182889T1 (de) Bicyclische amidinderivate als no-synthetase inhibitoren
DK160098C (da) Tricycliske oxindolcarboxamid-derivater
ES2152379T3 (es) Dihidropiridinas condensadas y su utilizacion para la produccion de preparados farmaceuticos.
KR850001319B1 (en) Process for preparing 1h-1,2,4-triazol derivatives
DE69514532T2 (de) Indol-2,3-dione-3-oximderivate, ihre herstellung und verwendung
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
NO922636L (no) Fremgangsmaate for fremstilling av 2,4-dihydro-2-alkyl-3-okso-2h-(1)benzotieno-(3,2-e)-1,2-tiazin-1,1-dioksyder
ATE66231T1 (de) Dioxolobenzisoxazolderivate und verfahren zu ihrer herstellung.